⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034856 | 1.00 | — | — | |
| SCHEMBL31118798 | 0.84 | — | — | |
| Trifluoroacetic Acid SCHEMBL14842738 | 0.82 | NOS2 (0.41) | — | |
| SCHEMBL165100 | 0.81 | — | — | |
| SCHEMBL105871 | 0.81 | — | — | |
| SCHEMBL115697 | 0.75 | — | — | |
| SCHEMBL390280 | 0.74 | — | — | |
| SCHEMBL247619 | 0.74 | — | — | |
| SCHEMBL13884662 | 0.74 | — | — | |
| SCHEMBL19341243 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4626888-A1 | COMPOUNDS | Redx Pharma Limited (GB) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024236452-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | JAZZ PHARMACEUTICALS IRELAND LTD. (IE) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024191996-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024115890-A1 | COMPOUNDS | REDX PHARMA PLC (GB) | 2024-06-06 | — | — | WO | disclosed |
| EP-4126843-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4041714-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |